Drugmaker seeks judicial review in CMA excessive-pricing case
The UK antitrust enforcer’s “manifestly” and “irrationally” wrong decision to refuse an extension for a defendant to respond to a supplementary statement of objections should be reviewed by a court, a pharmaceutical company has argued.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.